Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11382921
APP PUB NO 20210060035A1
SERIAL NO

16958575

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed is a use of 5α-androstane-3β,5,6β-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
GUANGZHOU CELLPROTEK PHARMACEUTICAL CO LTDGUANGZHOU GUANGDONG 510663

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Huang, Yijun Guangdong, CN 31 192
Lin, Suizhen Guangdong, CN 11 6
Yan, Guangmei Guangdong, CN 20 24
Yin, Wei Guangdong, CN 81 329

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 12, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 12, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 12, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00